Premium
Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum
Author(s) -
Shareef M. S.,
Munro L. R.,
Owen R. G.,
Highet A. S.
Publication year - 2012
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2011.04219.x
Subject(s) - pyoderma gangrenosum , medicine , dermatology , general hospital , infliximab , university hospital , multiple myeloma , family medicine , general surgery , library science , disease , computer science
Summary Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53‐year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma.